Micro Interventional Devices (MID) is an emerging medical device company that specializes in designing, manufacturing, and commercializing products for transcatheter cardiac repair procedures. Their transformative technology allows for the replication of established surgical structural heart repair procedures, but with the safety and convenience of transcatheter methods. By eliminating the need for open-heart surgery and cardiopulmonary bypass, MID aims to improve patient outcomes by reducing procedure time, hospital stay, and recovery time.

With a focus on addressing unmet needs in transcatheter mitral and tricuspid valve repair, MID's headquarters is located in Newtown, Pennsylvania. The company boasts a qualified team and infrastructure, with ISO 13485:2016 certification and an ISO Class 8 (100,000) manufacturing area. The experienced management team, with over 100+ years of combined experience in operations, manufacturing, and commercializing medical devices, has a proven track record of bringing disruptive technologies to the market.

MID's flagship product, the MIA-T System, is an Investigational Device that utilizes proprietary technology that is patent-protected. Streamlining cardiac repair procedures and ensuring patient safety, Micro Interventional Devices is revolutionizing the field of cardiology